Putting out the endless results whilst encouraging doesn’t really tell us much yet of any consequence.
When safety is proven/ accepted by the regulators and we have FDA and TGA feedback on specifics of data required for the IND and Priority registration we will know exactly where we are up to .
I am still very much on the page this is potentially a groundbreaker and happy to stay in . GLTAH and DYOR
Ann: Further Significant Improvement in Rett Syndrome Patients, page-12
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
